Satellos Bioscience Inc. MSCLF
6.25 USD 0.00 (+0.00%)
Apr 8, 2026, 9:30 AM EDT
5.77 Day range 6.39
0.88 52-week range 12.50
- YTD
- +6.29%
- 1 year
- -5.16%
News
marketbeat.com Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results Satellos Bioscience NASDAQ: MSLE said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living with Duchenne…
globenewswire.com Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially life-improving medicines to treat…
globenewswire.com Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET
globenewswire.com Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry Distinguished scientists bring expertise spanning…
globenewswire.com Satellos to Participate in Upcoming Investor Conferences TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle…
globenewswire.com Satellos Granted Composition of Matter Patent for Forazapadin Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development Composition of matter provides U.S. protection through Sept. 6, 2044, as…
globenewswire.com Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative…
globenewswire.com Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat…
globenewswire.com Satellos to Present at the 31st Annual Congress of the World Muscle Society TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative…
globenewswire.com Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle…
globenewswire.com Satellos to Participate in Upcoming Investor Conferences TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative…
globenewswire.com Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative…
marketbeat.com Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update Satellos Bioscience NASDAQ: MSLE said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne…
benzinga.com Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD)
globenewswire.com Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat…
globenewswire.com Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat…
globenewswire.com Satellos to Present Clinical Program Updates at ICNMD 2026 TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat…
globenewswire.com Satellos Bioscience Announces Results of Annual Meeting of Shareholders TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines…
globenewswire.com Satellos to Participate in Upcoming Investor Conferences TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines…
globenewswire.com Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines…